An observational study in Severe Combined Immunodeficiency Due to ADA Deficiency, sponsored by Fondazione Telethon. Completed at 1 site in Italy. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Fondazione Telethon · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is a Post-Authorization Measure to evaluate the accuracy and precision of retroviral insertion site (RIS) analysis and its utility for investigating and predicting the potential for insertional oncogenesis in subjects treated with Strimvelis.
This non-interventional, retrospective, methodology study will use peripheral blood and bone marrow samples previously taken from subjects treated with Strimvelis. The study does not require subjects to undergo any further treatment, intervention or blood withdrawal.
The objective of this methodology study is to evaluate the accuracy and precision of Sonication and Linker Mediated (SLiM) - PCR for RIS analysis and its utility for investigating and predicting the potential for insertional oncogenesis in subjects previously treated with Strimvelis for severe combined immunodeficiency (SCID) due to adenosine deaminase (ADA) deficiency.
29 studies on the registry are indexed under Severe combined immunodeficiency due to adenosine deaminase deficiency; 4 are open to participants now.
This study's enrollment of 23 is below the median of 76 across 13 observational studies indexed under Severe combined immunodeficiency due to adenosine deaminase deficiency.
Browse Severe combined immunodeficiency due to adenosine deaminase deficiency studies →Fondazione Telethon is the lead sponsor of 12 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Nov 17, 2026. See what changed
This study will use biological samples previously taken from subjects treated with Strimvelis gRV-GT.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must have previously received treatment with gRV-GT, either during clinical development (clinical trials and early access programs) or in the post-marketing setting as the approved product (Strimvelis) or under hospital exemption, and for whom at least one biological sample is available that meets the following eligibility criteria:
Exclusion Criteria N/A
Subjects who have previously received treatment with gRV-GT, either during clinical development (clinical trials and early access programs) or in the post-marketing setting as the approved product (Strimvelis) or under hospital exemption, and for whom at least one biological sample is available that meets the following eligibility criteria: * Peripheral blood, bone marrow, or DNA extracted from either source. * Taken at least 6 months after gRV-GT. * Stored at -20°C or below since the time of sampling. * Likely to provide 500 ng (maximum)of DNA (following extraction by the central laboratory).
Precision of SLiM-PCR Methodology for RIS Analysis Using Control Insertion Site DNA
Precision was measured as the percentage coefficient of variation (%CV) of the abundance.
Time frame: Retrospective analysis, samples obtained 6 months after gRV-GT, analysis over single day
Accuracy of SLiM-PCR Methodology for RIS Using Control Insertion Site DNA
Accuracy was determined based on the difference between the mean retrieved abundance and the expected abundance of control DNA.
Time frame: Retrospective analysis, samples obtained 6 months after gRV-GT, analysis over single day
Abundance of Insertion Sites in Subjects Treated With gRV-GT
Abundance was quantified by listing the top 10 most abundant clones for each sample, including the name of the targeted gene. The number of non-redundant IS retrieved was reported for the whole sample (Unique IS).
Time frame: Retrospective analysis, samples obtained 6 months after gRV-GT, analysis over single day
Diversity of Insertion Sites in Subjects Treated With gRV-GT
In terms of diversity of insertion sites, a total of 35,587 unique IS were identified across 16 patients and 70 samples (27 BM and 43 mPB).
Time frame: Retrospective analysis, samples obtained 6 months after gRV-GT, analysis over single day
| Milestone | Subjects Previously Treated With Strimvelis (or GSK2696273) Gene Therapy |
|---|---|
| Started | 23 |
| Completed | 17 |
| Not completed | 6 |
Precision was measured as the percentage coefficient of variation (%CV) of the abundance.
| % relative abundance | Subjects Previously Treated With Strimvelis (or GSK2696273) Gene Therapy |
|---|---|
| Precision of SLiM-PCR Methodology for RIS Analysis Using Control Insertion Site DNA | 0.1 |
Accuracy was determined based on the difference between the mean retrieved abundance and the expected abundance of control DNA.
| fold change | Subjects Previously Treated With Strimvelis (or GSK2696273) Gene Therapy |
|---|---|
| Accuracy of SLiM-PCR Methodology for RIS Using Control Insertion Site DNA | 1.5 ± 0.27 |
Abundance was quantified by listing the top 10 most abundant clones for each sample, including the name of the targeted gene. The number of non-redundant IS retrieved was reported for the whole sample (Unique IS).
| total unique IS | Subjects Previously Treated With Strimvelis (or GSK2696273) Gene Therapy |
|---|---|
| Abundance of Insertion Sites in Subjects Treated With gRV-GT | 35587 (187 to 9146) |
In terms of diversity of insertion sites, a total of 35,587 unique IS were identified across 16 patients and 70 samples (27 BM and 43 mPB).
| number of IS per patient | Subjects Previously Treated With Strimvelis (or GSK2696273) Gene Therapy |
|---|---|
| Diversity of Insertion Sites in Subjects Treated With gRV-GT | 2224 (187 to 9146) |
Collected over Not applicable/collected for this retrospective methodology study.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Subjects Previously Treated With Strimvelis (or GSK2696273) Gene Therapy | — | — | — |
Samples from 17 patients were included in the analysis: samples from 2 patients were used for the primary objective, and samples from 16 patients were used for the secondary objective, with one patient contributing to both analyses. To assess the accuracy and precision of SLiM-PCR, two samples were used.
| Age, Continuous(years) | Subjects Previously Treated With Strimvelis (or GSK2696273) Gene Therapy |
|---|---|
| Mean | 5.54 ± 4.07 |
| Sex: Female, Male(Participants) | Subjects Previously Treated With Strimvelis (or GSK2696273) Gene Therapy |
|---|---|
| Female | 9 |
| Male | 8 |
| Ethnicity (NIH/OMB)(Participants) | Subjects Previously Treated With Strimvelis (or GSK2696273) Gene Therapy |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 15 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2021 to primary completion in Feb 2024, 33 months.
Results were first posted in Nov 2026, 2 years 9 months after primary completion.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Mar 2024 → Feb 2024 and completion Mar 2024 → Jun 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Severe combined immunodeficiency due to adenosine deaminase deficiency →
Fondazione Telethon